Home | Medical-Newswire.Com:
(EMAILWIRE.COM, March 21, 2012 ) New York, NY -- NovaBay Pharmaceuticals (NBY) released news this week that offers to broaden the scope and reach of the company's Aganocide compounds, which are being positioned as anti-infectives and could potentially replace modern day antibiotics as resistance to such treatment grows.
On Tuesday NovaBay announced a deal with Virbac Animal Health to bring its technology to the veterinary market. According to the agreement, NovaBay will receive an upfront payment - and some additional support for research and development - while Virbac will retain the option to license any of the Aganocide compounds that are successfully applied to treating veterinary indications.
The deal could provide NovaBay with a steady revenue stream in the future if Virbac exercises its licensing option. According to the Tuesday press release, if the option is exercised,
"NovaBay may receive additional payments, which include an exercise fee as well as development and pre-commercial milestones for a line of veterinary products. NovaBay will also receive royalties on sales of any successfully commercialized Aganocide products to arise from this agreement."
Few companies are going to become superpowers in the field of medicine on treating veterinary indications alone, but the deal brings some attention back to NovaBay and gives us another chance to consider this company's technology on the open market - should the pipeline products make it that far.
It also gives us the opportunity to determine whether or not the current market capitalization for NBY justifies that pipeline potential, which, in the opinion of this writer, the determination is "probably not."
First, let's revisit the problem of antibiotic resistance.
When introduced into society seventy years ago, antibiotics changed the shape of medicine, and provided what - at the time - was considered a huge leap forward in treating bacterial infections. Having been so widely-used since then, however, the infectious organisms against which the antibiotics are administered have grown increasingly resistant, and sometimes immune, to today's antibiotic treatments.
The Centers for Disease Control and Prevention considers the developing resistance to antibiotics as a "crisis", noting on its website that, "These drugs have been used so widely and for so long that the infectious organisms the antibiotics are designed to kill have adapted to them, making the drugs less effective. People infected with antimicrobial-resistant organisms are more likely to have longer, more expensive hospital stays, and may be more likely to die as a result of the infection."
Medical professionals themselves understand the growing risks associated with antibiotic resistance, as noted by Dr. Marc Siegel, associate professor of medicine and medical director of Doctor Radio at NYU Langone Medical Center, this week in an article published on FoxNews.com. Dr. Siegel also notes that Doctors continue to over prescribe these treatments, thereby strengthening the resistance of the surviving bacteria and creating new "super colonies" that will eventually be uncontrollable.
This dilemma has created a huge monetary burden on the global health care system and is possibly setting up a one-time "miracle cure" as irrelevant.
That's where NovaBay comes into the picture.
NovaBay has developed, through its proprietary Aganocide compounds, a pipeline of synthetic anti-infectives that are designed to mimic the body's own defenses against infection. Namely, these synthetic molecules, based on the Aganocide compound NVC-422, essentially act in the same manner and processes of a body's white blood cells and not as antibiotics, therefore significantly reducing the risk of a resistance being developed.
The potential of such a technology has market-moving implications, and under the circumstances, it's understandable why NBY could be tagged with an 'undervalued' label.
There are, however, a couple of reasons why investors may not yet have fully embraced the company and its technology. The first reason may be the most obvious one; that NovaBay still has nothing beyond Phase II, and therefore any investment in the company is highly speculative and risky at this point, which is a fair assessment.
That said, the best deals in biotech are the ones that are found early, when patience is needed as the trial results pan out. It's also worth noting, however, that he trend of staying away from speculative "Phase II" investments may be shifting.
Take Lpath, Inc. (LPTN), for example. Lpath also has a novel and potentially groundbreaking technology in the works, but Pfizer (PFI) has bucked the Phase II label of the company and jumped in with a very significant partnership.
CellDex Therapeutics (CLDX) is another one that has traded very highly during its Phase II stages, even when Pfizer decided to divorce itself from a partnership with the company.
In both cases, investors may have started to become clued in to how much market potential is contained within those respective pipelines and tossed the standard "wait until Phase III" strategy to the side. As investors with similar strategies in mind research NovaBay, the same potential for price appreciation exists; especially give the fact that NBY has a powerhouse partner of its own in Galderma SA, with whom NovaBay is developing a treatment for the highly-contagious skin condition, Impetigo.
Another reason why NovaBay may be missing the mark in terms of market cap right now, and this one may be more relevant than the last, is that an earlier clinical trial conducted with then-partner Alcon in the treatment of adenoviral conjunctivits - better known to the average Joe as "pink eye" - failed.
Shares slumped badly after that news hit the presses and have only barely recovered since.
On the flip side to the endpoint miss, however, which sent sent investors running for the doors, is that a further look at the data from the same trial did show that efficacy was demonstrated against Epidemic Keratoconjunctivitis (EKC), possibly the most contagious form of the infection, and which often threatens a victim's vision.
Based on that data, trials have continued, but the fact that the company has a failed trial under its belt most certainly deters some investors from jumping back in, at least until they see more results.
A Phase IIb trial for this indication is expected to begin within months, while another Phase II trial for the Impetigo condition is also slated for this year.
Results from 'Part A' from a trial testing NVC-422 as a treatment for urinary catheter blockage and encrustation (UCBE) have already rolled in, with results from 'Part B' also due within months.
The pending trial results provide some short term catalysts, but another catalyst due for this year could be the one that puts NovaBay on the map.
A commercial launch is planned for the short to mid term for NeutroPhase, NBY's first FDA-cleared product and a treatment for chronic wound in both hospital and personal care. A successful launch for NeutroPhase could alleviate many of the monetary concerns normally associated with a small company bringing its pipeline through trials, and just a couple of months ago the company announced its first strategic partner for NeutroPhase.
Having a product already on the market and bringing in revenue will go a long way to validating this small company in the eyes of potential investors, especially if the NeutroPhase commercial launch goes off without a hitch.
Based on the pending trial catalysts, the commercial launch of NeutroPhase, and most importantly, the potential of NVC-422 products on the open market as eventual substitutes for antibiotics, NBY may still be trading under the radar and could still be lightly valued, when all is considered.
By 2013 the NovaBay could have three Phase III trials ongoing with an FDA approved product on the market.
If that's the case, it's a fair bet to assume that the market cap will be significantly higher than thirty five million at that point.
For an example of how a shift from Phase II to Phase III can effect a market cap, one could look at Keryx BioPharmaceuticals (KERX). During the early to mid stages of Phase II, the KERX market cap was similar to NBY's now, but when Phase II trials were successful and Phase III came along?
Prices quickly quadrupled.
NovaBay's target market of anti-infective care is a multi-multi-billion dollar market annually, and NBY could quickly penetrate that market, as Doctors are currently looking for a way around antibiotic resistance.
As I've previously discussed, this company may be at the right place at the right time. For investors being in the right place at the right time means being "in" before any price run starts, and it's possible that NBY has a ways to move, should the pending catalysts turn out positive.
Disclosure: Long NBY.
For more information and commentary regading NBY, visit: http://vfcsstockhouse.com/blog/article/-novabay-may-be-in-the-right-place-at-the-right-time-with-an-answer-for-antibiotic-resistance
Contact VFC's Stock House: email@example.com
VFC's Stock House offers research-based investment information, insights and ideas on a variety of different companies in numerous sectors, with a focus on biotech stocks and healthcare.
For full reports on Celsius Holdings and other companies visit: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on
top health stories.
University of Virginia suspends fraternal organizations in assaults probe
22 Nov 2014 at 2:29pm
(Reuters) - The University of Virginia is suspending all fraternal organizations until January after a magazine article described in detail an alleged sexual assault that occurred on the campus, the school said on Saturday. All fraternal organizations and associated social activities will shut down until Jan. 9, the beginning of the spring semester, so that students, faculty and alumni can address sexual assault and sexual violence on campus, said Teresa Sullivan, president of the prestigious state university, located in Charlottesville, about 100 miles southwest of Washington, D.C. ...
Aviva says will compensate customers sold wrong annuities
22 Nov 2014 at 11:17am
LONDON (Reuters) - British insurer Aviva plc said on Saturday it would compensate around 250 annuity customers who had been short-changed because of an error in its sales process. The Telegraph newspaper reported on Saturday that Aviva had discovered staff had sold hundreds of customers inappropriate pensions in 2013. Savers with medical conditions including diabetes, high blood pressure and smokers should have been offered an increased annuity - which provides an income for life - based on their lower life expectancy, the newspaper said. ...
Merkel ally warns SPD against own diplomacy towards Russia
22 Nov 2014 at 10:41am
BERLIN (Reuters) - A senior ally of German Chancellor Angela Merkel has warned the foreign minister and his fellow Social Democrats (SPD) against pursuing a more friendly approach towards Russia in the Ukraine crisis, according to Spiegel magazine. "I know Mr (Frank-Walter) Steinmeier as a sensible diplomat. And we also need the dialogue with Russia," Horst Seehofer, leader of the Bavarian Christian Social Union (CSU), was quoted as saying in an interview published on Saturday. ...
Germany reports second case of bird flu: H5N8 found in wild bird
22 Nov 2014 at 9:27am
BERLIN (Reuters) - German authorities on Saturday confirmed a second case of the H5N8 strain of bird flu in the eastern state of Mecklenburg-Vorpommern, with the virus found in a wild bird. The strain is highly contagious among birds but has never been detected in humans. "For the first time, the H5N8 virus has been confirmed in a wild bird in Mecklenburg-Vorpommern," Agriculture Minister Christian Schmidt said in a statement. ...
Mali: New Ebola case confirmed, 2 more suspected
22 Nov 2014 at 7:48am
BAMAKO, Mali (AP) ? Mali on Saturday confirmed a new case of Ebola and said two more suspected patients are being tested, raising concern about a further spread of the disease which has already killed at least five people in the country.
Pope meets with autistic children
22 Nov 2014 at 7:37am
VATICAN CITY (AP) ? Pope Francis tenderly embraced children with autism spectrum disorders, some of whom avoided meeting his gaze, during an audience Saturday aimed at offering solidarity to people living with the condition.
Mali records new Ebola case, linked to dead nurse
22 Nov 2014 at 7:00am
BAMAKO (Reuters) - Mali has recorded a new case of Ebola in the capital Bamako after the friend of a nurse who died of the hemorrhagic fever earlier this month tested positive for the disease, health and medical officials said on Saturday. The nurse contracted the disease after treating an imam from neighboring Guinea, who died after being incorrectly diagnosed with kidney problems. This allowed Ebola to spread to five other people in the West African nation's second outbreak. "Of two suspected cases tested, one was negative and the other positive. ...
Saudi Arabia tackles MERS virus, still hunting source
22 Nov 2014 at 6:32am
By Kate Kelland LONDON, (Reuters) - (This story corrects to make clear that the finding that 97 percent of cases were hospital-acquired was from a study of an outbreak in Jeddah, paragraph 10) Saudi Arabia has not yet traced the source of a mysterious camel virus, leaving many questions about a disease that has killed 346 people in the Kingdom. ...
UK volunteers fly to Sierra Leone to fight Ebola
22 Nov 2014 at 5:04am
FREETOWN, Sierra Leone (AP) ? The first wave of volunteers from Britain's National Health Service arrived in Sierra Leone Saturday amid what the World Health Organization has described as an "intense" surge in cases.
Plague outbreak kills 40 people in Madagascar
22 Nov 2014 at 3:22am
JOHANNESBURG (AP) ? A plague outbreak has killed 40 people on the island nation of Madagascar, with 119 people diagnosed with the bacterial disease since August.
Dutch to destroy 8,000 ducks to prevent bird flu outbreak
22 Nov 2014 at 2:24am
AMSTERDAM (Reuters) - Dutch health authorities on Saturday were destroying 8,000 ducks to prevent the possible spread of bird flu, which has infected three farms in a week in the Netherlands, a leading poultry and egg exporter. A government statement said ducks were being culled in the central town of Barneveld as a precaution because authorities want to eliminate all risks after the H5N8 virus spread to three out of 12 provinces since last Sunday. ...
International Ebola fight helping but more work needed -U.N. chief
22 Nov 2014 at 12:16am
WASHINGTON (Reuters) - International efforts to fight Ebola are helping to slow the rate of new infections in some areas but increased infections in others and fears of further contagion in Mali indicate much work is still to be done, United Nations Secretary-General Ban Ki-moon said on Friday. Ban said more trained medical teams are needed, especially in remote districts of countries in West Africa where more than 5,400 people have been killed by the virus. Ban said the coordinated efforts of country leaders and safer burial practices, combined with international support, are helping. ...
Car jackers in Guinea steal suspected Ebola blood samples
22 Nov 2014 at 12:03am
CONAKRY (Reuters) - Robbers in Guinea hijacked a Red Cross vehicle this week and made off with a cooler containing blood samples from suspected Ebola patients, a senior Red Cross official said on Friday. "No doubt they thought it was something else," Youssouf Traoré, head of the Red Cross delegation in Guinea, told Reuters. He gave no further details of the attack but said the robbers would probably dump the cooler once they found it did not contain gold or diamonds. More than 5,000 people have died in Guinea, Sierra Leone and Liberia in the worst outbreak of the Ebola virus on record.
Plague in Madagascar has killed 40 people out of 119 cases -WHO
22 Nov 2014 at 12:00am
GENEVA (Reuters) - An outbreak of the plague has killed 40 people out of 119 confirmed cases in Madagascar since late August and there is a risk of the disease spreading rapidly in the capital, the World Health Organization (WHO) said on Friday. So far two cases and one death have been recorded in the capital Antananarivo but those figures could climb quickly due to "the city's high population density and the weakness of the healthcare system", the WHO warned. ...
Ebola death toll rises to 5,459 - WHO
21 Nov 2014 at 11:57pm
GENEVA (Reuters) - The death toll in the Ebola epidemic has risen to 5,459 out of 15,351 cases identified in eight countries by the end of Nov. 18, the World Health Organization (WHO) said on Friday. The figures showed an increase of 39 recorded deaths and 106 new cases since those issued on Wednesday. "Transmission remains intense in Guinea, Liberia and Sierra Leone," the WHO said, referring to the hardest-hit countries. All six known Ebola cases in Mali have now died and 327 contacts exposed to the virus are being monitored in the capital Bamako, it said.